Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait

Radium-223 is the 1^st nuclide medicine from the group of alpha emitters, its use is associated with an increase in overall survival, a delay to bone complications and a significant improvement the quality of life, proven placebo-controlled randomized studies in patients with castration-resistant prostate cancer in the presence of bone metastases and no visceral ones. Perhaps the еarly use of radium-223 in combination with enzalutamide or abiraterone in castration-resistant prostate cancer patients with bone metastases, before the start of treatment with taxanes is reasonable.Today, the issue of embedding modern nuclide therapy in the accepted system of treating castration-resistant prostate cancer.

1. Ryan C.J., Smith M.R., Fizazi K. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2):152—60. DOI: 10.1016/S1470-2045(14)71205-7. PMID: 25601341.

2. Bubendorf L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578—83. DOI: 10.1053/hp.2000.6698. PMID: 10836297.

3. DePuy V., Anstrom K.J., Castel L.D. et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007;15(7):869—76. DOI: 10.1007/s00520-006-0203-x. PMID: 17262196.

4. Oefelein M.G., Ricchiuti V., Conrad W. et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168(3):1005—7. DOI: 10.1097/01.ju.0000024395.86788.cc. PMID: 12187209.

5. Coleman R., Brown J., Terpos E. et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34(7):629—39. DOI: 10.1016/j.ctrv.2008.05.001. PMID: 18579314.

6. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513—20. DOI: 10.1056/NEJMoa041318. PMID: 15470214.

7. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502—12. DOI: 10.1056/NEJMoa040720. PMID: 15470213.

8. Attard G., Parker C., Eeles R.A. et al. Prostate cancer. Lancet 2015. DOI: 10.1016/S0140-6736(14)61947-45.

9. Falkmer U., Jarhult J., Wersall P. et al. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003;42(5—6):620—33. PMID: 14596519.

10. Zotov P.B., Kudryakov A.Yu., Zuev V.Yu. et al. Model of the system of accounting for chronic pain syndrome in the oncological clinic. Academicheskiy zhurnal Zapadnoy Sibiri = Academic Journal of Western Siberia 2018;14(2):70—2. (In Russ.).

11. Bilen M.A., Johnson M.M., Mathew P. et al. Randomized phase 2 study of bonetargeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 2015;121(1):69—76. DOI: 10.1002/cncr.28971. PMID: 25155428.

12. Parker C., Gillessen S., Heidenreich A. et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):69—77. DOI: 10.1093/annonc/mdv222. PMID: 26205393.

13. Krylov V.V., Kochetova T.Yu., Voloznev L.V. Radionuclide therapy for bone metastases. New opportunities. Voprosy oncologii = Questions of Oncology 2015; 61 (1): 14-9. (In Russ.).

14. Brady D., Parker C., O’Sullivan J.M. Bone¬targeting radiopharmaceuticals including radium-223. Cancer J 2013;19(1):71-8. DOI: 10.1097/PPO.0b013e318282479b. PMID: 23337760.

15. Townsend P.W., Rosenthal H.G., Smalley S.R. et al. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol 1994;12(11):2345—50. DOI: 10.1200/JCO.1994.12.11.2345. PMID: 7669102.

16. Schulte M., Hartwig E., Sarkar M. et al. Endoprosthetic treatment of metastatic pathological fractures. Anticancer Res 1998;18(3C):2251 —2. PMID: 9703795.

17. Heianna J., Toita T., Endo W. et al. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience. Ann Nucl Med 2015;29(10):848—53. DOI: 10.1007/s12149-15-1010-6. PMID: 26266885.

18. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J.Med 2013;369(3):213—23. DOI: 10.1056/NEJ-Moa1213755. PMID: 23863050.

19. Bruland O.S., Nilsson S., Fisher D.R. et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12(20):6250s—7s. DOI: 10.1158/1078-0432.CCR-06-0841. PMID: 17062709.

20. Nilsson S., Larsen R.H., Fossa S.D. et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451 —9. DOI: 10.1158/1078-0432.CCR-04-2244. PMID: 15958630.

21. Nilsson S., Franzen L., Parker C. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587—94. DOI: 10.1016/S1470-2045(07)70147-X. PMID: 17544845.

22. Saad F., Gleason D.M., Murray R. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458—68. DOI: 10.1093/jnci/94.19.1458. PMID: 12359855.

23. Fizazi K., Carducci M., Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813—22. DOI: 10.1016/S0140-6736(10)62344-6. PMID: 21353695.

24. Sartor O., Coleman R., Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7)738—46. DOI: 10.1016/S1470-2045(14)70183-4. PMID: 24836273.

25. Sonpavde G., Pond G.R., Berry W.R. et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012;30(5):607—13. DOI: 10.1016/j.urolonc.2010.07.002. PMID: 20888271.

26. Wymenga L.F., Boomsma J.H., Groenier K. et al. Routine bone scans in patients with prostate cancer related to serum prostatespecific antigen and alkaline phosphatase. BJU Int 2001;88(3):226—30. DOI: 10.1046/j.1464-410x.2001.02275.x. PMID: 11488734.

27. Nilsson S. Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep 2016;18(2):14. DOI:10.1007/s11912-015-0495-4. PMID: 26779616.

28. Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf 2015;14(7):1127— 36. DOI: 10.1517/14740338.2015.1045874. PMID: 26022669.

29. Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397—406. DOI: 10.1016/S1470-2045(14)70474-7. PMID: 25439694.

30. Humm J.L., Sartor O., Parker C. et al. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. Int J Radiat Oncol Biol Phys 2015;91(5):898—906. DOI: 10.1016/j.ijrobp.2014.12.061. PMID: 25832684.

31. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995—2005. DOI: 10.1056/NEJMoa1014618.

32. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187—97. DOI: 10.1056/NEJMoa1207506. PMID: 22894553.

33. Vbgelzang N.J., Fernandez D.C., Morris M.J. et al. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). J Clin Oncol 2015;33(Suppl 7):abstr. 247.

34. Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306-16. DOI: 10.1016/S1470-2045(16)30173-5. PMID: 27473888.